Business Context and Reporting Period
This Form 8-K was filed by PerkinElmer, Inc. (Note: The metadata lists "REVVITY, INC.", but the filing text identifies the registrant as PerkinElmer, Inc.) on January 11, 2021. The report primarily addresses the ongoing acquisition of Oxford Immunotec Global PLC ("Oxford") and the company's presentation at the 2021 J.P. Morgan Healthcare Conference.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. This document serves as a current report on material events rather than a financial statement.
Material Changes and Events
- Acquisition Update: On January 7, 2021, PerkinElmer, PerkinElmer (UK) Holdings Limited, and Oxford entered into an Implementation Agreement for PerkinElmer to acquire Oxford. This filing references that agreement and notes that further details will be in a forthcoming scheme document and proxy statement.
- Conference Presentation: On January 11, 2021, the Company presented at the 2021 J.P. Morgan Healthcare Conference. Presentation materials and a transcript of the oral presentation are attached as Exhibits 99.1 and 99.2.
Guidance, Outlook, and Risks
The filing contains a "Cautionary Statement Concerning Forward-Looking Statements." Management notes that statements regarding future earnings, cash flow, revenue growth, and the acquisition are based on current assumptions and are subject to significant risks. Key risks identified include:
- Failure to satisfy closing conditions for the Oxford acquisition, including shareholder approval and court sanction.
- Uncertainties regarding the timing of the acquisition's consummation.
- Disruption to business operations and retention of employees due to the acquisition.
- Impact of the COVID-19 pandemic on sales and operations.
- Global economic and political fluctuations, including the UK's withdrawal from the European Union.
- Regulatory compliance challenges in the healthcare industry.
Investors are urged to read the upcoming scheme document and proxy statement for detailed information regarding the acquisition.
Important Facts for Investor Verification
- Verify the final terms and conditions of the Oxford Immunotec acquisition in the upcoming scheme document and proxy statement.
- Confirm the status of regulatory approvals and shareholder votes required to close the acquisition.
- Review the attached presentation materials (Exhibit 99.1) and transcript (Exhibit 99.2) for specific management commentary on the J.P. Morgan Healthcare Conference.
- Note that the registrant name in the filing is PerkinElmer, Inc., not REVVITY, INC.